That brand is more than just a logo - it’s your company’s reputation ... The company launched a new visual identity and a new brand purpose: to “unite science, talent and technology to ...

Gilead Sciences, Inc. (NASDAQ:GILD), a leading biopharmaceutical company with a market capitalization of $119.32 billion, has been making significant strides in its core HIV franchise while expanding ...

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $115.00.

In a report released yesterday, Mohit Bansal from Wells Fargo maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of $105.00. Mohit Bansal has given his Buy ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. Galapagos NV plans to split into two entities ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Gilead Sciences has taken a major step towards ... significant milestones in two pivotal Phase 3 trials PURPOSE 1 and PURPOSE 2. Data from both studies showcased the superiority of twice-yearly ...

For 2025, Browning has another “Radical In The Family” with its new X-Bolt 2 All Purpose bolt-action rifle. Many would put the All Purpose in the “ranch rifle” category, but to be frank ...

After hours: 7:59:47 p.m. EST ...